Teva Pharmaceutical (TEVA) Tops Q4 EPS by 1c

Teva Pharmaceutical (NASDAQ: TEVA) reported Q4 EPS of $1.59, $0.01 better than the analyst estimate of $1.58. Revenue for the quarter came in at $5.68 billion versus the consensus estimate of $5.61 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Carnival shares drop despite earnings beat on weak guidance